99% Savings - Buy Just @1 Rs X
Caberlin 0.25 Mg Tablet is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of Acromegaly, Prolactinoma.
The right dosage of Caberlin 0.25 Mg Tablet depends on the age, gender, and medical history of the patient. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
Some other side effects of Caberlin 0.25 Mg Tablet have been listed ahead. These side effects of Caberlin 0.25 Mg Tablet are usually temporary and subside with the completion of treatment. If, however, they worsen or do not go away, please speak with your physician.
It is also important to note that Caberlin 0.25 Mg Tablet has a Mild effect for pregnant women and Severe effect on lactating mothers. Further, the section on Caberlin 0.25 Mg Tablet related warnings talks about Caberlin 0.25 Mg Tablet's effects on the liver, heart and kidney.
Caberlin 0.25 Mg Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. High Blood Pressure, Heart Disease, Depression are examples of such conditions. Other conditions have been mentioned below in the Caberlin 0.25 Mg Tablet contraindications section.
Additionally, Caberlin 0.25 Mg Tablet may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Caberlin 0.25 Mg Tablet is considered not safe while driving, and is not addictive.
Caberlin 0.25 Mg Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Caberlin 0.25 Mg Tablet safe for pregnant women?
Pregnant women may get mild side effects from Caberlin.
Is the use of Caberlin 0.25 Mg Tablet safe during breastfeeding?
Caberlin may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Caberlin 0.25 Mg Tablet on the Kidneys?
There may be some adverse effects on kidney after taking Caberlin. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Caberlin 0.25 Mg Tablet on the Liver?
Caberlin can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Caberlin 0.25 Mg Tablet on the Heart?
Caberlin may cause harmful effects on the heart. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
If you are suffering from any of the following diseases, you should not take Caberlin 0.25 Mg Tablet unless your doctor advises you to do so -
Is this Caberlin 0.25 Mg Tablet habit forming or addictive?
Caberlin 0.25 Mg Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
After taking Caberlin 0.25 Mg Tablet you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Caberlin 0.25 Mg Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
No, Caberlin 0.25 Mg Tablet is not used to treat mental disorders.
Interaction between Food and Caberlin 0.25 Mg Tablet
Information is not available on the interaction of any foods with Caberlin 0.25 Mg Tablet, due to a lack of research on this.
Interaction between Alcohol and Caberlin 0.25 Mg Tablet
Drinking alcohol while taking Caberlin 0.25 Mg Tablet may lead to slight side effects. If you experience any side effects, contact your doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 174-176
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 239-240
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Dostinex® (cabergoline)